1. Home
  2. BBLG vs OGEN Comparison

BBLG vs OGEN Comparison

Compare BBLG & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BBLG

Bone Biologics Corp

HOLD

Current Price

$1.22

Market Cap

2.3M

Sector

Health Care

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.60

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBLG
OGEN
Founded
2004
1996
Country
United States
United States
Employees
2
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3M
2.7M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
BBLG
OGEN
Price
$1.22
$0.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.7K
40.9K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$0.11
52 Week High
$5.98
$9.16

Technical Indicators

Market Signals
Indicator
BBLG
OGEN
Relative Strength Index (RSI) 39.46 47.51
Support Level $1.08 $0.56
Resistance Level $1.40 $0.66
Average True Range (ATR) 0.06 0.04
MACD -0.01 0.00
Stochastic Oscillator 0.00 44.49

Price Performance

Historical Comparison
BBLG
OGEN

About BBLG Bone Biologics Corp

Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: